PMID- 37273263
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230606
IS  - 1319-0164 (Print)
IS  - 2213-7475 (Electronic)
IS  - 1319-0164 (Linking)
VI  - 31
IP  - 7
DP  - 2023 Jul
TI  - Jordanians' knowledge, attitude and practice regarding adverse drug reactions 
      reporting.
PG  - 1197-1201
LID - 10.1016/j.jsps.2023.05.016 [doi]
AB  - OBJECTIVES: The purpose of the current study was to evaluate the general public 
      knowledge, attitudes, and practice regarding Adverse Drug Reactions (ADRs) 
      reporting and pharmacovigilance in Jordan. METHODS: A cross-sectional study was 
      conducted between July 16, 2022, and July 30, 2022, in Jordan. During the study 
      period, an electronic survey consisting of 4 sections was administered to a 
      convenience sample of Jordanians (aged 18 or above) using 2 social media 
      platforms (Facebook and WhatsApp). Logistic regression analysis was used to 
      screen the predictors of ADRs reporting by the participants. RESULTS: A total of 
      441 participants completed the survey. The majority of the participants (67.6%) 
      were females, 53.1% between 26 and 45 years old. Almost all participants (96.3%) 
      were always aware of the indication of the medications they take, the time and 
      frequency (87.8%), and the duration of medications (84.4%). Nearly one-third of 
      the participants (37.4%) asked about their medications' ADRs. However, the drug 
      information leaflet was the most frequently used source of ADR information 
      (33.3%). The majority of responders believed that both healthcare providers and 
      consumers should report ADRs (93.4% and 80.3%, respectively). Only one-quarter of 
      respondents (27.2%) believed that consumers could directly report ADRs through 
      the Jordan pharmacovigilance program. The majority of patients who had 
      experienced ADRs (70.3%) were aware that ADRs should be reported, and among them, 
      91.9% had reported the ADRs to healthcare providers. Furthermore, few 
      participants (8.1%) reported it to the Jordan National Pharmacovigilance Centre 
      (JNCP). Linear regression revealed that none of the demographic characteristics 
      (age, gender, education, job, and social status) were affecting public reporting 
      practice of the ADRs (P > 0.05 for all). CONCLUSION: Respondents showed fair 
      knowledge about adverse drug reactions and their reporting. However, there is a 
      need to initiate educational activities and intervention programs to raise 
      awareness about the JNPC, which will have a positive impact on public health and 
      ensure safe medication use in Jordan.
CI  - (c) 2023 The Author(s).
FAU - El-Dahiyat, Faris
AU  - El-Dahiyat F
AD  - Clinical Pharmacy Program, College of Pharmacy, Al Ain University, Al Ain, United 
      Arab Emirates.
AD  - AAU Health and Biomedical Research Center, Al Ain University, Abu Dhabi, United 
      Arab Emirates.
FAU - Abu Hammour, Khawla
AU  - Abu Hammour K
AD  - Department of Biopharmaceutics and Clinical Pharmacy, Faculty of Pharmacy, the 
      University of Jordan, Amman, Jordan.
FAU - Abu Farha, Rana
AU  - Abu Farha R
AD  - Department of Clinical Pharmacy and Therapeutics, Faculty of Pharmacy, Applied 
      Science Private University, Amman, Jordan.
FAU - Manaseer, Qusai
AU  - Manaseer Q
AD  - Orthopedic Department, Jordan University Teaching hospital, Amman, Jordan.
FAU - Al Momanee, Ala'a
AU  - Al Momanee A
AD  - Pharmacy Department, Jordan University Teaching Hospital, Amman, Jordan.
FAU - Allan, Aya
AU  - Allan A
AD  - Pharmacy Department, Jordan University Teaching Hospital, Amman, Jordan.
FAU - Alkhawaldeh, Rama
AU  - Alkhawaldeh R
AD  - Department of Clinical Pharmacy and Therapeutics, Faculty of Pharmacy, Applied 
      Science Private University, Amman, Jordan.
LA  - eng
PT  - Journal Article
DEP - 20230518
PL  - Saudi Arabia
TA  - Saudi Pharm J
JT  - Saudi pharmaceutical journal : SPJ : the official publication of the Saudi 
      Pharmaceutical Society
JID - 9705695
PMC - PMC10236368
OTO - NOTNLM
OT  - Adverse drug reaction
OT  - Jordan
OT  - Knowledge
OT  - Pharmacovigilance
COIS- The authors declare that they have no known competing financial interests or 
      personal relationships that could have appeared to influence the work reported in 
      this paper.
EDAT- 2023/06/05 13:04
MHDA- 2023/06/05 13:05
PMCR- 2023/05/18
CRDT- 2023/06/05 11:45
PHST- 2023/04/05 00:00 [received]
PHST- 2023/05/13 00:00 [accepted]
PHST- 2023/06/05 13:05 [medline]
PHST- 2023/06/05 13:04 [pubmed]
PHST- 2023/06/05 11:45 [entrez]
PHST- 2023/05/18 00:00 [pmc-release]
AID - S1319-0164(23)00135-4 [pii]
AID - 10.1016/j.jsps.2023.05.016 [doi]
PST - ppublish
SO  - Saudi Pharm J. 2023 Jul;31(7):1197-1201. doi: 10.1016/j.jsps.2023.05.016. Epub 
      2023 May 18.